Education
About Us
Working with TipRanks
Follow Us
Fate Therapeutics (FATE)
NASDAQ:FATE
Total Valuation
Fate Therapeutics has a market cap or net worth of $123.40M. The enterprise value is -$8.74M.
Market Cap$123.40M
Enterprise Value-$8.74M
Share Statistics
Fate Therapeutics has 115,329,700 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding115,329,700
Owned by Insiders12.95%
Owned by Institutions23.44%
Financial Efficiency
Fate Therapeutics’s return on equity (ROE) is -0.58 and return on invested capital (ROIC) is -50.43%.
Return on Equity (ROE)-0.58
Return on Assets (ROA)-0.42
Return on Invested Capital (ROIC)-50.43%
Return on Capital Employed (ROCE)-0.52
Revenue Per Employee75.31K
Profits Per Employee-1.03M
Employee Count181
Asset Turnover0.03
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Fate Therapeutics is ―. Fate Therapeutics’s PEG ratio is ―.
PE Ratio―
PS Ratio―
PB Ratio―
Price to Fair Value0.59
Price to FCF―
Price to Operating Cash Flow-1.16
PEG Ratio―
Income Statement
In the last 12 months, Fate Therapeutics had revenue of 13.63M and earned -186.26M in profits. Earnings per share was -1.64.
Revenue13.63M
Gross Profit13.63M
Operating Income-210.28M
Pretax Income-186.26M
Net Income-186.26M
EBITDA-176.58M
Earnings Per Share (EPS)-1.64
Cash Flow
In the last 12 months, operating cash flow was -115.61M and capital expenditures -3.15M, giving a free cash flow of -118.77M billion.
Operating Cash Flow-115.61M
Free Cash Flow-118.77M
Free Cash Flow per Share-1.03
Dividends & Yields
Fate Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.70
52-Week Price Change-69.97%
50-Day Moving Average1.18
200-Day Moving Average1.43
Relative Strength Index (RSI)49.34
Average Volume (3m)1.37M
Important Dates
Fate Therapeutics upcoming earnings date is Oct 30, 2025, TBA (Confirmed).
Last Earnings DateAug 12, 2025
Next Earnings DateOct 30, 2025
Ex-Dividend Date―
Financial Position
Fate Therapeutics as a current ratio of 7.58, with Debt / Equity ratio of 31.12%
Current Ratio7.58
Quick Ratio7.58
Debt to Market Cap0.04
Net Debt to EBITDA-0.28
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Fate Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Fate Therapeutics EV to EBITDA ratio is -1.34, with an EV/FCF ratio of -1.92.
EV to Sales17.37
EV to EBITDA-1.34
EV to Free Cash Flow-1.92
EV to Operating Cash Flow-1.93
Balance Sheet
Fate Therapeutics has $222.83M in cash and marketable securities with $81.33M in debt, giving a net cash position of -$141.50M billion.
Cash & Marketable Securities$222.83M
Total Debt$81.33M
Net Cash-$141.50M
Net Cash Per Share-$1.23
Tangible Book Value Per Share$2.80
Margins
Gross margin is 61.30%, with operating margin of -1542.63%, and net profit margin of -1366.46%.
Gross Margin61.30%
Operating Margin-1542.63%
Pretax Margin-1366.46%
Net Profit Margin-1366.46%
EBITDA Margin-1295.41%
EBIT Margin-1434.52%
Analyst Forecast
The average price target for Fate Therapeutics is $3.08, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target$3.08
Price Target Upside182.57% Upside
Analyst ConsensusHold
Analyst Count8
Revenue Growth Forecast-31.23%
EPS Growth Forecast14.92%